Cohen Yuval 4

Accession 0000950170-24-075071

CIK 0001595097other

View on SEC.gov Company Profile

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 5:58 PM ET

Size

42.6 KB

Accession

0000950170-24-075071

Insider Transaction Report

Form 4

Period: 2024-06-14

Corbus Pharmaceuticals Holdings, Inc.CRBP

Cohen Yuval

DirectorChief Executive Officer

Transactions

Sale
Common Stock, par value $0.0001 per share
2024-06-14$50.17/sh−16,830$844,297→ 84,400 total
Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−7,179$303,219→ 77,221 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$30.00/sh+11,667$350,010→ 96,067 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$4.26/sh+1,770$7,540→ 86,170 total
Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.02/sh−1,770$81,456→ 84,400 total
Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−11,667$492,779→ 84,400 total
Exercise/Conversion
Options to purchase common stock
2024-06-14−12,487→ 53,831 total
Exercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (12,487 underlying)
Exercise/Conversion
Options to purchase common stock
2024-06-18−1,770→ 31,057 total
Exercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (1,770 underlying)
Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−2,322$98,074→ 84,400 total
Exercise/Conversion
Options to purchase common stock
2024-06-14−16,830→ 32,827 total
Exercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (16,830 underlying)
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$14.10/sh+16,830$237,303→ 101,230 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$4.26/sh+12,487$53,195→ 96,887 total
Sale
Common Stock, par value $0.0001 per share
2024-06-14$50.17/sh−12,487$626,425→ 84,400 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$14.10/sh+1,770$24,957→ 86,170 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$4.26/sh+2,322$9,892→ 86,722 total
Exercise/Conversion
Options to purchase common stock
2024-06-17−1,770→ 52,061 total
Exercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (1,770 underlying)
Exercise/Conversion
Options to purchase common stock
2024-06-18−2,322→ 49,739 total
Exercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (2,322 underlying)
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$30.00/sh+9,333$279,990→ 93,733 total
Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.02/sh−9,333$429,507→ 84,400 total
Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.24/sh−1,770$74,759→ 84,400 total
Exercise/Conversion
Options to purchase common stock
2024-06-17−9,333→ 11,667 total
Exercise: $30.00Exp: 2024-10-22→ Common Stock (9,333 underlying)
Exercise/Conversion
Options to purchase common stock
2024-06-18−11,667→ 0 total
Exercise: $30.00Exp: 2024-10-22→ Common Stock (11,667 underlying)

Footnotes (8)

[F1]This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
[F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F6]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.
[F7]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
[F8]The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Corbus Pharmaceuticals Holdings, Inc.

CIK 0001595097

→

Entity typeother

Related Parties

filerCIK 0001626003

Filing Metadata

Form type: 4
Filed: Jun 17, 8:00 PM ET
Accepted: Jun 18, 5:58 PM ET
Size: 42.6 KB

View on SEC.gov